Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015–2018

[1] Bilous M(2003)Current perspectives on HER2 testing: a review of national testing guidelines Mod Pathol 16 173-182

[2] Dowsett M(2010)American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Oncol Pract 6 243-246

[3] Hanna W(2011)Quality assessment of HER2 testing by monitoring of positivity rates Virchows Arch 459 283-289

[4] Isola J(2001)Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups Cancer 92 37-45

[5] Lebeau A(2014)Distribution pattern of the Ki67 Labelling Index in breast cancer and its implications for choosing cut-off values Breast 23 259-263

[6] Moreno A(2017)De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017 Ann Oncol 28 1700-1712

[7] Burstein HJ(2007)Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 1504-1513

[8] Griggs JJ(2000)Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 36 170-176

[9] Prestrud AA(2017)Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM) Eur J Cancer 75 284-298

[10] Temin S(2011)Her2 amplification status in Iranian breast cancer patients: comparison of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) Asian Pac J Cancer Prev 12 1031-1034

[1] Bilous M(2003)Current perspectives on HER2 testing: a review of national testing guidelines Mod Pathol 16 173-182

[2] Dowsett M(2010)American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Oncol Pract 6 243-246

[3] Hanna W(2011)Quality assessment of HER2 testing by monitoring of positivity rates Virchows Arch 459 283-289

[4] Isola J(2001)Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups Cancer 92 37-45

[5] Lebeau A(2014)Distribution pattern of the Ki67 Labelling Index in breast cancer and its implications for choosing cut-off values Breast 23 259-263

[6] Moreno A(2017)De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017 Ann Oncol 28 1700-1712

[7] Burstein HJ(2007)Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 1504-1513

[8] Griggs JJ(2000)Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 36 170-176

[9] Prestrud AA(2017)Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM) Eur J Cancer 75 284-298

[10] Temin S(2011)Her2 amplification status in Iranian breast cancer patients: comparison of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) Asian Pac J Cancer Prev 12 1031-1034